Semaglutide injection shortage history
FDA · FDA Drug Shortage Database · 2025
ReviewDocuments the ongoing supply constraints for semaglutide injection products, which have driven demand for compounded alternatives.
SemaglutidePubMed
Research
Peer-reviewed research briefs and curated studies from the published peptide literature.
Research Briefs
Why 70% Stop GLP-1s: The Real Discontinuation Data
Peer-Reviewed· Unable to retrieve journal information · 2026
May 28, 2026·4 min read
New real-world data reveals massive dropout rates from GLP-1 medications — and the reasons aren't what you'd expect from clinical trials.
discontinuationreal-world-dataadherenceRead brief →
Methylglyoxal Breaks RNA: A New Mechanism of Metabolic Damage
Peer-Reviewed· bioRxiv · 2026
May 28, 2026·4 min read
Glucose byproduct methylglyoxal doesn't just damage proteins—it also glycates RNA, creating a novel stress response that could explain glucose toxicity.
methylglyoxalrna-glycationmetabolic-stressRead brief →
BPC-157's Formulation Problem: Why Most Products Don't Work
Peer-Reviewed· Unable to determine from provided information · 2026
May 27, 2026·4 min read
New analysis reveals the massive stability and bioavailability challenges plaguing BPC-157 products—explaining inconsistent user results.
BPC-157peptide-stabilitybioavailabilityRead brief →
GLP-1 Drugs May Be Damaging Your Eyes
Peer-Reviewed· Unable to retrieve from signal · 2026
May 27, 2026·4 min read
New analysis reveals concerning patterns of eye complications with semaglutide and other GLP-1 agonists that weren't caught in trials.
side-effectsglp-1visionRead brief →
Why 40% of Patients Quit GLP-1 Meds (And What Happens Next)
Peer-Reviewed· Journal not available from provided information · 2026
May 27, 2026·4 min read
Large cohort reveals GI side effects drive most discontinuations, but weight regain happens fast when patients stop these medications.
discontinuationside-effectsweight-regainRead brief →
Your Glucose Spikes Are Breaking Your RNA
Peer-Reviewed· bioRxiv · 2026
May 27, 2026·4 min read
New data shows methylglyoxal from glucose metabolism directly damages mRNA, triggering stress cascades that could explain metabolic dysfunction.
glucosemetabolismstressagingRead brief →
Tirzepatide's Sleep Apnea Fix May Be More Than Weight Loss
Peer-Reviewed· Unable to retrieve from provided information · 2026
May 27, 2026·4 min read
New data suggests tirzepatide improves obstructive sleep apnea through mechanisms beyond simple weight reduction.
tirzepatidesleep-apneaweight-lossRead brief →
Your Cells Are Sugar-Coating Their Own RNA to Death
Peer-Reviewed· bioRxiv · 2026
May 26, 2026·4 min read
New research shows methylglyoxal from sugar metabolism directly modifies RNA, triggering stress responses that kill pancreatic cells.
metabolic-stressdiabetesRNA-modificationmethylglyoxalRead brief →
Why Half of GLP-1 Users Quit — The Real Discontinuation Data
Peer-Reviewed· Not available from provided summary · 2026
May 25, 2026·4 min read
New real-world data reveals the primary drivers behind GLP-1 receptor agonist discontinuation and what happens when patients stop.
discontinuationreal-world-datapatient-outcomesRead brief →
GLP-1/GIP Combos: Why Tirzepatide Wins But Questions Remain
Peer-Reviewed· Unable to retrieve from provided information · 2026
May 25, 2026·4 min read
New analysis breaks down why dual GLP-1/GIP agonists work better than monotherapy, but missing mechanistic data leaves key questions unanswered.
tirzepatidecombination-therapymechanismsRead brief →
NASH Treatment Pipeline Finally Gets Real Options
Peer-Reviewed· Unable to determine from provided information · 2026
May 25, 2026·4 min read
First comprehensive look at approved and emerging NASH therapies shows promising mechanisms but highlights the massive clinical gap.
NASHmetabolic-healthliver-diseaseRead brief →
MASH Drug Pipeline: GLP-1s Lead, But Gaps Remain
Peer-Reviewed· Unable to retrieve journal information · 2026
May 24, 2026·4 min read
Review maps current MASH therapeutics landscape. GLP-1 agonists dominate approvals, but mechanism gaps suggest combination approaches ahead.
MASHGLP-1liverRead brief →
NASH Treatment Pipeline: What Actually Works in 2025
Peer-Reviewed· Unable to retrieve from provided summary · 2026
May 23, 2026·4 min read
New NASH therapies show promise, but the bar for liver histology improvement remains high. Here's what's working in trials.
NASHlivermetabolicRead brief →
Semaglutide Rescues Failed Bariatric Surgery Patients
Peer-Reviewed· Journal not available from provided data · 2026
May 23, 2026·4 min read
New RCT shows semaglutide can salvage weight loss in bariatric surgery failures—but raises questions about surgical durability.
semaglutidebariatric-surgeryweight-regainRead brief →
Semaglutide + Surgery: Stacking GLP-1 for Extreme Weight Loss
Peer-Reviewed· Not available from provided data · 2026
May 23, 2026·4 min read
New data shows combining semaglutide with sleeve gastrectomy drives superior weight loss versus surgery alone—but at what metabolic cost?
semaglutidebariatric-surgeryweight-lossRead brief →
GLP-1/GIP Combos: The Mechanism Behind Tirzepatide's Dominance
Peer-Reviewed· Journal information not available · 2026
May 22, 2026·4 min read
New mechanistic data explains why dual GLP-1/GIP agonists outperform single-target therapies for weight loss and glycemic control.
glp-1gipdual-agonistsweight-lossRead brief →
Why 70% Quit GLP-1s: The Real Dropout Data
Peer-Reviewed· Journal not specified in signal · 2026
May 22, 2026·4 min read
New discontinuation data reveals the gap between clinical trials and reality for semaglutide, liraglutide, and tirzepatide users.
GLP-1adherencereal-world-dataRead brief →
NASH Drug Pipeline: GLP-1s Lead, But Liver-Specific Targets Emerge
Peer-Reviewed· Unable to retrieve from provided information · 2026
May 22, 2026·4 min read
Review of NASH therapeutics shows GLP-1 agonists dominating near-term approvals, while novel liver-specific mechanisms offer differentiated approaches.
NASHGLP-1liver-healthRead brief →
Flu Shots Are Getting Weaker — And It's Not Just Age
Peer-Reviewed· medRxiv (preprint) · 2026
May 21, 2026·4 min read
A decade of serological data reveals flu vaccine antibody responses have been systematically declining since 2018, independent of age or prior vaccination.
vaccinesantibody-responseimmune-systemRead brief →
NASH Treatment Pipeline: Why Current Approvals Miss the Mark
Peer-Reviewed· Unable to determine from provided information · 2026
May 21, 2026·4 min read
New NASH therapies are getting approved, but the mechanisms tell a different story about what actually works for fatty liver disease.
NASHfatty-livermetabolic-healthRead brief →
MASLD Drug Pipeline Shows Promise — But Timing Still Unclear
Peer-Reviewed· Unable to retrieve from signal · 2026
May 20, 2026·4 min read
Current MASLD therapies fall short, but emerging GLP-1 combinations and FXR agonists may finally deliver meaningful liver protection.
MASLDNAFLDliver-healthdrug-developmentRead brief →
Tirzepatide Shows Alzheimer's Protection in Rats — But Don't Skip the GLP-1s Yet
Peer-Reviewed· Unable to determine from provided information · 2026
May 20, 2026·4 min read
New rat data shows tirzepatide reduces neuroinflammation and apoptosis in an AD model, but the mechanisms aren't unique to dual agonism.
tirzepatidealzheimersneuroprotectionRead brief →
Tirzepatide's CKM Benefits May Start Earlier Than Expected
Peer-Reviewed· Data not available from provided information · 2026
May 20, 2026·4 min read
New analysis suggests tirzepatide's cardiovascular-kidney-metabolic benefits emerge faster than traditional outcome trials capture.
tirzepatidecardiovascularmetabolicGLP-1Read brief →
Flu Vaccine Immunity Is Collapsing Across All Age Groups
Peer-Reviewed· medRxiv · 2026
May 19, 2026·4 min read
Massive dataset shows vaccine antibody responses dropping since 2018—age and boosters don't explain the decline.
immunologyvaccinesagingRead brief →
MASLD Drug Pipeline: Beyond GLP-1s for Fatty Liver
Peer-Reviewed· Unable to retrieve from provided information · 2026
May 19, 2026·4 min read
New therapeutic targets emerge for metabolic liver disease as the field moves past simple weight loss approaches toward targeted hepatic interventions.
MASLDliver-healthmetabolic-dysfunctionRead brief →
NASH Drug Pipeline: Why Current Approval Standards Miss the Mark
Peer-Reviewed· Unable to retrieve from provided information · 2026
May 18, 2026·4 min read
A comprehensive review of NASH therapeutics reveals a disconnect between regulatory endpoints and real-world metabolic outcomes.
NASHmetabolic-dysfunctiondrug-developmentRead brief →
Semaglutide Shows Promise for Alcohol Use Disorder
Peer-Reviewed· Journal not available from provided data · 2026
May 18, 2026·4 min read
New research suggests GLP-1 agonists like semaglutide may reduce alcohol consumption through novel dopaminergic pathways.
semaglutideaddictionglp-1Read brief →
When GLP-1 Agonists Shut Down Your Gut for Weeks
Peer-Reviewed· Unable to extract - limited access · 2026
May 18, 2026·4 min read
A tirzepatide overdose triggered week-long paralytic ileus in a bulimia patient—revealing serious gastroparesis risks few discuss.
case-reportadverse-effectsgastroparesisRead brief →
GHK-Cu Shows Longevity Promise, But It's Still Just Worms
Peer-Reviewed· Information not available from provided abstract · 2026
May 17, 2026·4 min read
New C. elegans data shows GHK-Cu extends lifespan via FOXO activation and mitochondrial protection—but clinical relevance remains unproven.
longevitymitochondriaantioxidantsRead brief →
GHK-Cu Shows Real Longevity Effects — But Only In Worms
Peer-Reviewed· Data not available from provided signal · 2026
May 16, 2026·4 min read
New C. elegans data shows GHK-Cu extends lifespan 20% via mitochondrial pathways. The mechanism looks solid, but worm results rarely translate to humans.
GHK-CulongevitymitochondriaRead brief →
GHK-Cu Extends Worm Lifespan via DAF-16 — But Translation Remains Murky
Peer-Reviewed· Data not available from provided information · 2026
May 15, 2026·4 min read
C. elegans study shows GHK-Cu activates key longevity pathways, but the massive dose-response gap from worm to human raises serious questions.
GHK-CulongevitymitochondriaRead brief →
Retatrutide Rewrites Metabolic Profiles Beyond Weight Loss
Peer-Reviewed· Journal not specified in provided data · 2026
May 15, 2026·4 min read
New metabolomic data shows retatrutide's triple receptor agonism creates systemic metabolic changes that go far beyond GLP-1 alone.
retatrutidemetabolomicstriple-agonistRead brief →
Million-Person Study Maps Genetic Roots of Blood Cell Aging
Peer-Reviewed· medRxiv (preprint) · 2026
May 14, 2026·4 min read
Massive genetic analysis reveals 72 loci driving clonal hematopoiesis—the blood cell dysfunction that accelerates aging and disease risk.
geneticsaginghematopoiesisRead brief →
GHK-Cu Shows Real Longevity Effects in Worms—But Don't Get Excited Yet
Peer-Reviewed· Journal not available from provided data · 2026
May 14, 2026·4 min read
C. elegans lived 25% longer on GHK-Cu via mitochondrial optimization and stress response pathways. Classic longevity mechanisms, but worms aren't humans.
ghk-culongevitymitochondriaRead brief →
Retatrutide's Triple Action: Too Good to Be True for CKM Syndrome?
Peer-Reviewed· Journal not available from provided information · 2026
May 14, 2026·4 min read
Comprehensive review examines retatrutide's GLP-1/GIP/glucagon triple agonism for cardiovascular-kidney-metabolic syndrome. The mechanisms look promising, but we need real outcomes data.
retatrutideckm-syndrometriple-agonistRead brief →
GHK-Cu Shows Longevity Effects via DAF-16/SKN-1 in Worms
Peer-Reviewed· Journal not provided in source · 2026
May 13, 2026·4 min read
New data shows GHK-Cu extends C. elegans lifespan through mitochondrial optimization and stress response pathways. Worm data, but mechanism matters.
ghk-culongevitymitochondriaRead brief →
GLP-1s + Bariatric Surgery: The Data on Doubling Down
Peer-Reviewed· Journal not available from provided information · 2026
May 13, 2026·4 min read
New review examines whether combining GLP-1 agonists with weight loss surgery amplifies results or creates unnecessary complexity.
GLP-1bariatric-surgeryweight-losscombination-therapyRead brief →
Mushroom Research Has Zero Relevance to Peptides or Health Optimization
Peer-Reviewed· bioRxiv · 2026
May 13, 2026·4 min read
Agricultural study on mushroom crop protection offers no insights for human health, peptides, or longevity protocols.
agricultureirrelevantmisclassifiedRead brief →
Semaglutide Crosses the Blood-Brain Barrier — With Alzheimer's Implications
Peer-Reviewed· Journal not available from provided information · 2026
May 13, 2026·4 min read
New mouse data shows semaglutide directly targets brain inflammation in Alzheimer's models, suggesting GLP-1 agonists work beyond metabolic pathways.
semaglutideneuroinflammationalzheimersglp1Read brief →
GHK-Cu Extends Lifespan 18% in Worms via FOXO Activation
Peer-Reviewed· Data not available from provided information · 2026
May 12, 2026·4 min read
New C. elegans data shows GHK-Cu extends lifespan through mitochondrial optimization and stress response pathways—but worm studies don't predict human outcomes.
ghk-culongevitymitochondriaRead brief →
GHK-Cu Reduces Inflammation in Zebrafish — But Context Matters
Peer-Reviewed· Journal not available from provided data · 2026
May 12, 2026·4 min read
New zebrafish data shows GHK-Cu dampens inflammatory responses, but the model limitations make clinical extrapolation premature.
GHK-CuinflammationzebrafishcopperRead brief →
Plant Genome Study Shows Nothing for Human Longevity
Peer-Reviewed· bioRxiv · 2026
May 11, 2026·4 min read
Duckweed genome research has zero application to peptides, longevity, or human optimization despite aquatic adaptation insights.
irrelevantbasic-researchgenomicsRead brief →
Duckweed Evolution: Why This Plant Study Matters for Longevity
Peer-Reviewed· bioRxiv · 2026
May 10, 2026·4 min read
Duckweeds evolved extreme genomic plasticity to adapt to aquatic life. Their chromosomal flexibility mechanisms could inform human aging research.
genomicsevolutionplasticityRead brief →
Mushroom Study Irrelevant to Human Optimization
Peer-Reviewed· bioRxiv · 2026
May 10, 2026·4 min read
Agricultural biocontrol research on mushroom parasites has zero relevance to peptide protocols or human longevity interventions.
irrelevantagriculturemicrobiomeRead brief →
Duckweed Genomes Reveal Aquatic Adaptation — But No Peptide Relevance
Peer-Reviewed· bioRxiv preprint · 2026
May 9, 2026·4 min read
Plant genomics study offers zero insights for human optimization. Sometimes basic research stays basic.
genomicsevolutionirrelevantRead brief →
GLP-1s Improve Quality of Life — But the Measure Matters
Peer-Reviewed· Journal not provided in signal · 2026
May 9, 2026·4 min read
Real-world study shows GLP-1 agonists boost quality of life scores, but methodology gaps leave key questions about durability unanswered.
quality-of-lifereal-world-evidencemethodologyRead brief →
Why Most Obesity Drugs Still Miss the Mark
Peer-Reviewed· Unable to determine from provided information · 2026
May 9, 2026·4 min read
New pharmacotherapy review reveals gaps in current obesity treatments and highlights where peptides excel.
obesitypharmacotherapyweight-lossRead brief →
Why Studying Plant Genomics Won't Fix Your Longevity Stack
Peer-Reviewed· bioRxiv preprint · 2026
May 8, 2026·4 min read
Interesting evolutionary biology on aquatic plant adaptation, but zero relevance to peptides, hormones, or human optimization.
research-methodologyevolutionary-biologygenomicsRead brief →
Duckweed Genome Offers Zero Insights for Human Health
Peer-Reviewed· bioRxiv · 2026
May 7, 2026·4 min read
Plant genomics paper on aquatic adaptation has no relevance to peptides, longevity, or human optimization. Skip this one entirely.
genomicsirrelevantplantsRead brief →
SCAD's Genetic Mystery: Why Women's Hearts Tear Without Warning
Peer-Reviewed· medRxiv preprint · 2026
May 6, 2026·4 min read
New exome sequencing data reveals the genetic blind spots in spontaneous coronary dissection—a condition that strikes healthy women.
cardiovasculargeneticswomens-healthRead brief →
Duckweed Genome Study: Zero Relevance for Human Health Optimization
Peer-Reviewed· bioRxiv · 2026
May 5, 2026·4 min read
Plant genomics research on aquatic adaptation has no bearing on peptide therapy, longevity protocols, or human health optimization strategies.
research-critiqueirrelevant-studiesplant-genomicsRead brief →
SCAD Genetics: Why Heart Attacks in Young Women Need Different Rules
Peer-Reviewed· medRxiv · 2026
May 5, 2026·4 min read
Swedish genetic data reveals spontaneous coronary artery dissection isn't just bad luck—it's heritable. Time to rethink cardiovascular risk in women.
cardiovasculargeneticswomen's-healthRead brief →
AI Outperforms Doctors at Predicting Critical Care Outcomes
Peer-Reviewed· medRxiv (preprint) · 2026
May 4, 2026·4 min read
Large language models matched or exceeded physician accuracy in prognosticating critically ill patients, raising questions about clinical decision-making.
artificial-intelligencecritical-careclinical-decision-makingRead brief →
SCAD Genetics: Another Strike Against the 'Healthy Heart' Myth
Peer-Reviewed· medRxiv (preprint) · 2026
May 4, 2026·4 min read
Swedish study finds genetic variants in 1 in 4 women with spontaneous coronary dissection—even those deemed 'low risk' by conventional metrics.
cardiovasculargeneticswomen's healthRead brief →
AI Doctors vs Real Doctors: Who Calls Death Better?
Peer-Reviewed· medRxiv (preprint) · 2026
May 3, 2026·4 min read
Large language models matched physician accuracy in predicting critical care mortality, but the real question is whether either approach actually improves patient outcomes.
artificial-intelligencecritical-caremortality-predictionRead brief →
GLP-1 Agonists May Lower Suicide Risk - But Don't Ignore The Signal
Peer-Reviewed· Unable to determine from provided information · 2026
May 3, 2026·4 min read
New analysis suggests semaglutide and tirzepatide might reduce suicidal ideation, but the mechanism remains unclear and individual responses vary.
moodmental-healthsafetyRead brief →
SCAD Genetics: Why Heart Attacks Hit Healthy Young Women
Peer-Reviewed· medRxiv (preprint) · 2026
May 3, 2026·4 min read
Swedish genetic study reveals why spontaneous coronary artery dissection strikes women without traditional cardiac risk factors.
cardiologygeneticswomen's healthRead brief →
Wegovy HD: More Semaglutide, Diminishing Returns
Peer-Reviewed· Not specified in brief format · 2026
May 3, 2026·4 min read
New high-dose semaglutide formulation shows marginal weight loss gains over standard dosing, but side effect profile likely unchanged.
semaglutideweight-lossglp-1dosingRead brief →
Exercise Foundation Starts in Childhood — New African Data
Peer-Reviewed· medRxiv · 2026
May 2, 2026·4 min read
Zambian study reveals critical gaps in childhood physical activity that predict adult metabolic dysfunction. Early intervention matters more than we thought.
exercisepediatricmetabolic-healthRead brief →
Hypothalamic Obesity: When Your Brain's Energy Boss Goes Rogue
Peer-Reviewed· Journal not specified in provided data · 2026
May 2, 2026·4 min read
New expert consensus reveals why brain injuries cause unstoppable weight gain and what actually works to treat it.
hypothalamusobesitybrain-injurymetabolismRead brief →
Oral Semaglutide Gets a Chemistry Upgrade
Peer-Reviewed· Unable to extract from provided information · 2026
May 2, 2026·4 min read
New ionic liquid technology could finally make oral GLP-1 agonists practical by solving the absorption problem that's plagued peptide delivery.
oral-deliverypeptide-formulationdiabetesRead brief →
SCAD's Genetic Mystery: Why Heart Attacks Strike Young Women
Peer-Reviewed· medRxiv · 2026
May 2, 2026·4 min read
New genetic data reveals why spontaneous coronary dissection hits young, healthy women — and what it means for prevention.
geneticscardiovascularwomens-healthRead brief →
Bioengineering Won't Fix Peptide Delivery — Yet
Peer-Reviewed· bioRxiv · 2026
May 1, 2026·4 min read
Advanced plate engineering for fracture repair shows promise, but the real challenge remains optimizing healing compounds at the cellular level.
bioengineeringhealingmaterialsRead brief →
Childhood Inactivity Crisis Mirrors Adult Metabolic Dysfunction
Peer-Reviewed· medRxiv · 2026
May 1, 2026·4 min read
Zambian school data shows physical inactivity patterns in kids that predict the same metabolic disasters we see in sedentary adults.
exercisemetabolismpreventionRead brief →
Why This Jaw Surgery Study Misses the Longevity Connection
Peer-Reviewed· bioRxiv preprint · 2026
May 1, 2026·4 min read
Mandibular fracture fixation research ignores systemic inflammation and healing cascades that could inform peptide therapy protocols.
orthopedicsinflammationhealingRead brief →
SCAD Genetics: Why Your Heart Attack Risk Isn't Just About Cholesterol
Peer-Reviewed· medRxiv (preprint) · 2026
May 1, 2026·4 min read
Swedish study reveals spontaneous coronary artery dissection hits young women without traditional risk factors—genetics may explain why.
cardiovasculargeneticswomen-healthRead brief →
Physical Activity in Kids: Zambian Study Shows Movement Gaps
Peer-Reviewed· medRxiv · 2026
May 1, 2026·4 min read
Cross-sectional study of 638 Zambian children reveals physical activity patterns and barriers — limited relevance to peptide optimization protocols.
physical-activitypediatricepidemiologyRead brief →
Zambian Kids' Activity Data Shows Early Intervention Need
Peer-Reviewed· medRxiv · 2026
May 1, 2026·4 min read
Cross-sectional study of 638 Zambian children reveals concerning physical inactivity patterns that mirror metabolic dysfunction pathways we see in adults.
exercisemetabolismpreventionRead brief →
Peptide Longevity Claims vs. Reality Check
Peer-Reviewed· Data not available from signal · 2026
April 30, 2026·4 min read
A new review on therapeutic peptides for aging reveals more hype than hard data. Here's what actually works and what doesn't.
longevityagingpeptidesRead brief →
Titanium vs Steel: Why Plate Material Barely Matters for Jaw Fractures
Peer-Reviewed· bioRxiv · 2026
April 30, 2026·4 min read
Finite element analysis reveals plate design trumps material choice in mandibular fracture stability—contradicting titanium marketing hype.
biomechanicsmaterialssurgeryRead brief →
Zambian Kids Show Physical Activity Patterns — Not Peptide News
Peer-Reviewed· medRxiv · 2026
April 30, 2026·4 min read
Cross-sectional study of 638 Zambian children shows standard physical activity patterns. Relevant for baseline health, not peptide optimization.
physical-activitypediatricepidemiologyRead brief →
Your Fat Tissue Is Hijacking Your Brain's Hunger Signals
Peer-Reviewed· Unable to retrieve from provided information · 2026
April 29, 2026·4 min read
New research reveals how inflamed fat tissue creates a vicious cycle of neuroinflammation that drives compulsive eating and metabolic dysfunction.
neuroinflammationmetabolic-dysfunctionweight-regulationRead brief →
Peptide Gerontology Claims Need Mechanism-Based Evidence
Peer-Reviewed· Journal not specified · 2026
April 29, 2026·4 min read
Review paper on therapeutic peptides for aging lacks the mechanistic rigor needed to separate marketing from medicine.
agingpeptideslongevityRead brief →
Surgical Hardware Gets Smarter — But Misses the Real Story
Peer-Reviewed· bioRxiv preprint · 2026
April 29, 2026·4 min read
New finite element modeling improves mandibular fracture fixation design, but ignores the peptides driving actual bone healing.
orthopedicsbioengineeringbone-healingRead brief →
Weight Rebounds Fast After Tirzepatide—But Not How You Think
Peer-Reviewed· Not available from provided information · 2026
April 29, 2026·4 min read
New data reveals the metabolic mechanisms behind post-tirzepatide weight regain—it's not just appetite returning.
tirzepatideweight-lossglp1-agonistsRead brief →
Peptide Longevity Claims Need Better Data
Peer-Reviewed· Unable to retrieve from limited signal · 2026
April 28, 2026·4 min read
A review of therapeutic peptides in aging reveals promising mechanisms but highlights the gap between preclinical promise and clinical proof.
longevitypeptidesagingmechanismsRead brief →
Geriatric Peptide Hype Check: What Actually Works for Aging
Peer-Reviewed· Journal not available from provided information · 2026
April 27, 2026·4 min read
A new review examines therapeutic peptides for healthy aging, but separates the mechanistic promise from clinical reality.
agingpeptideslongevityRead brief →
Gerontology Peptide Review Lacks Clinical Depth
Peer-Reviewed· Journal not available from provided information · 2026
April 26, 2026·4 min read
Broad review of anti-aging peptides hits familiar targets but offers little actionable clinical insight beyond what we already know.
longevityreviewclinical-applicationRead brief →
Engineering Study Shows Titanium Still Rules for Facial Trauma
Peer-Reviewed· bioRxiv preprint · 2026
April 26, 2026·4 min read
Finite element analysis confirms titanium's superiority over steel and magnesium for jaw fracture plates, but the real insights lie in the biomechanics.
biomaterialstitaniumsurgical-hardwareRead brief →
Gerontology Peptides: Review Without the Research
Peer-Reviewed· Unable to determine from provided information · 2026
April 25, 2026·4 min read
Another therapeutic peptide review that skips the mechanistic data we actually need to evaluate anti-aging claims.
anti-agingresearch-qualitypeptide-mechanismsRead brief →
Why Jaw Surgery Studies Don't Belong in Longevity Research
Peer-Reviewed· bioRxiv (preprint) · 2026
April 25, 2026·4 min read
Biomedical engineering studies on mandibular fracture plates have zero relevance to peptide research or longevity optimization.
research-methodologyrelevancebioengineeringRead brief →
Why This Dental Surgery Study Matters for Peptide Users
Peer-Reviewed· bioRxiv · 2026
April 24, 2026·4 min read
Mandibular fracture repair research reveals tissue healing dynamics that directly apply to how peptides accelerate recovery.
tissue-repairhealingsurgery-recoveryRead brief →
The Peptide Longevity Stack: More Hype Than Science?
Peer-Reviewed· Unable to access journal information · 2026
April 24, 2026·4 min read
New gerontology review promises therapeutic peptides for healthy aging, but the evidence remains scattered across multiple mechanisms.
longevitypeptidesagingmechanismsRead brief →
Semaglutide Reverses Biological Age in NAFLD Patients
Peer-Reviewed· Journal information not available · 2026
April 24, 2026·4 min read
First study shows GLP-1 agonist reduces epigenetic aging markers in fatty liver disease—but sample size is tiny.
epigenetic-agingmetabolic-healthliver-healthRead brief →
GLP-1 Agonists and Blindness: Separating Signal from Noise
Peer-Reviewed· Unable to extract from provided information · 2026
April 23, 2026·4 min read
New analysis dissects whether semaglutide and tirzepatide actually cause vision loss, or if we're seeing confounding in high-risk populations.
safetycardiovascularvisionRead brief →
GLP-1 Muscle Loss Finally Gets a Real Study Protocol
Peer-Reviewed· Journal not provided in signal · 2026
April 23, 2026·4 min read
The LEAN-PREP trial will actually measure what happens to muscle mass with resistance training during semaglutide therapy. About time.
GLP-1muscle-preservationresistance-trainingRead brief →
Peptide Longevity Claims Need Better Evidence
Peer-Reviewed· Unable to retrieve - URL appears invalid · 2026
April 23, 2026·4 min read
Review of therapeutic peptides for aging reveals promising mechanisms but lacks the clinical data needed to justify current protocols.
agingclinical-evidencemechanismsRead brief →
Semaglutide May Slow Biological Aging Beyond Weight Loss
Peer-Reviewed· Unable to access journal information from provided information · 2026
April 23, 2026·4 min read
SLIM LIVER pilot data suggests GLP-1 agonists could decelerate biological aging markers, adding longevity benefits to metabolic effects.
semaglutideepigenetic-agingmetabolic-healthRead brief →
Dual Receptor Targeting Beats Semaglutide for Weight Loss
Peer-Reviewed· Unable to extract from provided summary · 2026
April 22, 2026·4 min read
New dual receptor agonists targeting GIPR and GCGR showed superior weight loss compared to GLP-1 monotherapy in obese rodents.
weight-lossdual-agonistsmetabolic-healthRead brief →
GLP-1 Agonist Clears Autoimmune Skin Disease in Single Case
Peer-Reviewed· Not available from provided information · 2026
April 22, 2026·4 min read
Tirzepatide completely resolved lichen planus in one patient, suggesting GLP-1/GIP agonists may modulate autoimmune inflammation.
tirzepatideautoimmuneinflammationRead brief →
Semaglutide Reverses Biological Age — First Longevity Data
Peer-Reviewed· Data not available from signal · 2026
April 22, 2026·4 min read
Pilot data shows semaglutide doesn't just drive weight loss — it actually reverses epigenetic aging markers. Small study, big implications.
epigenetic-agingmetabolic-healthclinical-dataRead brief →
One Semaglutide Pancreatitis Case Doesn't Change Risk Calculus
Peer-Reviewed· Unable to access journal details from provided summary · 2026
April 22, 2026·4 min read
Single case report adds to known pancreatitis risk profile but doesn't alter the well-established safety data from 100,000+ patient trials.
semaglutidesafetypancreatitisRead brief →
Tirzepatide Muscle Loss: When GLP-1s Strip More Than Fat
Peer-Reviewed· Journal not specified in summary · 2026
April 22, 2026·4 min read
New tirzepatide data reveals concerning muscle loss patterns that could undermine metabolic gains from rapid weight reduction.
tirzepatidemuscle-lossbody-compositionRead brief →
GLP-1 Agonist Clears Autoimmune Skin Disease: One Case Study
Peer-Reviewed· Not available from provided summary · 2026
April 21, 2026·4 min read
Single patient with lichen planus achieved complete remission on tirzepatide. Intriguing but we need controlled data.
tirzepatideautoimmunecase-reportRead brief →
Semaglutide Review Dodges the Real Off-Label Questions
Peer-Reviewed· Unable to access journal information · 2026
April 21, 2026·4 min read
Narrative review skims efficacy data but ignores practical realities of semaglutide use in healthy adults seeking weight loss.
semaglutideweight-lossoff-labelGLP-1Read brief →
Tirzepatide Pushes 90% Into Lower BMI Categories — But That's Not the Real Story
Peer-Reviewed· Data not available from signal · 2026
April 21, 2026·4 min read
SURMOUNT data shows tirzepatide moves patients down BMI categories, but the cardiometabolic improvements tell us more about GLP-1/GIP mechanisms than BMI math.
tirzepatideobesitycardiometabolicRead brief →
Tirzepatide Preserves Muscle While Improving Glucose Control
Peer-Reviewed· Unable to retrieve from summary · 2026
April 21, 2026·4 min read
New data suggests tirzepatide's muscle-sparing effects may directly correlate with better glycemic outcomes during weight loss.
muscle-preservationglucose-controlbody-compositionRead brief →
GLP-1 Receptor Agonist Clears Stubborn Skin Condition
Peer-Reviewed· Unable to determine from provided information · 2026
April 20, 2026·4 min read
Case report shows tirzepatide completely cleared treatment-resistant lichen planus, suggesting GLP-1/GIP pathways may modulate inflammatory skin conditions.
tirzepatideinflammationautoimmuneRead brief →
GLP-1 Shows Promise for Rare Mitochondrial Diabetes
Peer-Reviewed· Unable to determine from provided information · 2026
April 20, 2026·4 min read
Single case report suggests semaglutide improved metabolic markers in mitochondrial diabetes. Interesting mechanism, but one patient doesn't change protocols.
mitochondrial-healthcase-reportmetabolic-dysfunctionRead brief →
Incretins Strip Muscle Along With Fat — New Meta-Analysis
Peer-Reviewed· Journal not specified in provided data · 2026
April 20, 2026·4 min read
Fresh systematic review shows GLP-1 agonists cause significant lean mass loss compared to diet interventions. The muscle preservation myth dies here.
GLP-1body compositionmuscle lossRead brief →
GHK-Cu Delivery Gets an Upgrade, But Does It Matter?
Peer-Reviewed· Information not available from provided summary · 2026
April 19, 2026·4 min read
New hydroxyapatite microsphere delivery system for GHK-Cu shows promise in vitro, but clinical relevance remains unclear.
delivery-systemsanti-agingwound-healingRead brief →
Tirzepatide Preserves Muscle During Weight Loss—But Not How You'd Think
Peer-Reviewed· Journal not specified in provided data · 2026
April 19, 2026·4 min read
New data suggests tirzepatide's muscle-sparing effects may work through glucose regulation rather than direct anabolic pathways.
tirzepatidemuscle-preservationglucose-metabolismRead brief →
GHK-Cu Dermal Delivery: Promising In Vitro, Missing In Vivo
Peer-Reviewed· Unable to access journal information · 2026
April 18, 2026·4 min read
New hydroxyapatite microsphere system delivers GHK-Cu tripeptide effectively in lab tests, but clinical relevance remains unclear without human data.
GHK-Cudermal-deliveryanti-agingRead brief →
Tirzepatide's Muscle-Sparing Effect Links to Better Blood Sugar
Peer-Reviewed· Journal not available from provided data · 2026
April 18, 2026·4 min read
New data shows preserving lean mass during tirzepatide therapy correlates with better glucose control—suggesting muscle quality matters as much as weight loss.
tirzepatidebody-compositionglucose-metabolismRead brief →
GHK-Cu Filler Shows Promise, But Questions Remain
Peer-Reviewed· Journal not specified · 2026
April 17, 2026·4 min read
New delivery system for GHK-Cu shows anti-inflammatory effects, but study design limits clinical translation potential.
GHK-Cudelivery-systemsanti-inflammatoryRead brief →
Tirzepatide Muscle Loss Link Challenges Weight Loss Protocols
Peer-Reviewed· Unable to determine from provided information · 2026
April 17, 2026·4 min read
New analysis reveals patients who lost more muscle mass on tirzepatide had worse glucose control, suggesting muscle preservation isn't just cosmetic.
GLP-1muscle-preservationglucose-controlRead brief →
Injectable GHK-Cu: More Biotech Marketing Than Breakthrough
Peer-Reviewed· Journal not provided in PubMed signal · 2026
April 16, 2026·4 min read
Researchers loaded GHK-Cu into hydroxyapatite microspheres for injection. Interesting delivery system, but weak study design limits clinical relevance.
GHK-Cudelivery-systemsanti-inflammatoryRead brief →
Tirzepatide's Muscle-Sparing Effect May Improve Glucose Control
Peer-Reviewed· Unable to access journal information · 2026
April 16, 2026·4 min read
New data suggests preserving lean mass during GLP-1/GIP therapy directly correlates with better glycemic markers.
tirzepatidemuscle-preservationglucose-controlRead brief →
GHK-Cu Hydrogel Shows Promise, But Delivery Still the Challenge
Peer-Reviewed· Not available from provided data · 2026
April 15, 2026·4 min read
New hydroxyapatite microsphere formulation improves GHK-Cu stability and bioactivity, but real-world absorption remains questionable.
delivery-systemsbiomaterialswound-healingRead brief →
GHK-Cu Hydroxyapatite Delivery: Clever Chemistry, Missing Data
Peer-Reviewed· Journal not available from provided information · 2026
April 15, 2026·4 min read
New injectable filler combines GHK-Cu with hydroxyapatite microspheres. The delivery mechanism is sound, but clinical endpoints are absent.
GHK-Cudelivery-systemsinflammationRead brief →
GHK-Cu Gets Buried in Bone Filler — Novel Delivery or Wasted Potential?
Peer-Reviewed· Unable to retrieve journal information · 2026
April 15, 2026·4 min read
Researchers packaged GHK-Cu into bone microspheres for facial fillers. Clever delivery system, but we need human data on bioavailability.
ghk-cudelivery-systemsanti-agingRead brief →
GLP-1 Agonist Clears Autoimmune Skin Disease
Peer-Reviewed· Unable to determine from provided information · 2026
April 15, 2026·4 min read
Case report shows tirzepatide completely cleared treatment-resistant lichen planus, suggesting GLP-1/GIP agonists may have broader immunomodulatory effects.
tirzepatideautoimmunecase-reportRead brief →
GHK-Cu Filler Shows Promise But Needs Human Validation
Peer-Reviewed· Journal not available from provided data · 2026
April 14, 2026·4 min read
Injectable hydroxyapatite loaded with GHK-Cu demonstrates anti-inflammatory effects in vitro, but clinical relevance remains unclear.
ghk-cuanti-inflammatorydermal-fillersRead brief →
GHK-Cu Injectable Filler: Real Anti-Aging or Cosmetic Hype?
Peer-Reviewed· Unable to retrieve journal information · 2026
April 14, 2026·4 min read
New hydroxyapatite filler loaded with GHK-Cu shows anti-inflammatory effects, but does it deliver on anti-aging promises?
GHK-Cudermal fillersanti-inflammatoryRead brief →
GHK-Cu Shows Promise in Injectable Form, But It's Just Mice
Peer-Reviewed· Unable to retrieve journal information · 2026
April 14, 2026·4 min read
New delivery system for GHK-Cu shows anti-inflammatory effects in mice, but human translation remains uncertain.
GHK-Cupeptidesinflammationdelivery-systemsRead brief →
GHK-Cu Gets a Delivery Upgrade: Microsphere Math
Peer-Reviewed· Data not available from provided summary · 2026
April 14, 2026·4 min read
Hydroxyapatite microspheres extend GHK-Cu release, but the anti-inflammatory claims need better controls before clinical translation.
delivery-systemsanti-agingtissue-engineeringRead brief →
GHK-Cu Delivery System Shows Promise, But Missing Key Data
Peer-Reviewed· Journal information not available · 2026
April 13, 2026·4 min read
New injectable delivery system for GHK-Cu shows anti-inflammatory effects in vitro, but lacks the pharmacokinetic data needed for clinical relevance.
GHK-Cudelivery-systemsinflammationRead brief →
GHK-Cu Delivery Gets an Upgrade — But Does It Matter?
Peer-Reviewed· Journal not specified · 2026
April 13, 2026·4 min read
New hydroxyapatite microsphere delivery system for GHK-Cu shows promise in vitro, but the real question is whether delivery was ever the bottleneck.
ghk-cudelivery-systemsanti-inflammatoryRead brief →
GLP-1 Agonists Hit Two Birds: Weight Loss AND Smoking Cessation
Peer-Reviewed· Unable to retrieve journal information · 2026
April 13, 2026·4 min read
New research suggests GLP-1 receptor agonists like semaglutide may reduce nicotine cravings through shared dopamine pathways.
GLP-1addictiondopamineRead brief →
Not All GLP-1s Are Equal for Heart Disease
Peer-Reviewed· Not available from provided information · 2026
April 13, 2026·4 min read
Network meta-analysis ranks GLP-1 receptor agonists for cardiovascular outcomes. Semaglutide and dulaglutide emerge as clear winners.
cardiovasculardiabetesmeta-analysisRead brief →
GLP-1 Drugs May Crush Nicotine Cravings
Peer-Reviewed· Journal not available from provided data · 2026
April 13, 2026·4 min read
New evidence suggests semaglutide and similar GLP-1 agonists could be repurposed for smoking cessation through dopamine pathway modulation.
glp-1addictionsemaglutideRead brief →
GLP-1 May Actually Help You Quit Smoking
Peer-Reviewed· Journal not available from provided data · 2026
April 13, 2026·4 min read
Early evidence suggests GLP-1 receptor agonists could reduce nicotine cravings through dopamine pathway modulation, but we need controlled trials.
GLP-1addictionbehavioral-healthRead brief →
Mining GLP-1 Case Reports: What Real-World Data Reveals
Peer-Reviewed· medRxiv · 2026
April 13, 2026·4 min read
New analysis of 136 case reports using AI timeline extraction reveals temporal patterns in GLP-1 receptor agonist therapy that standard trials miss.
glp1case-reportsreal-world-dataRead brief →
Rybelsus/Ozempic Rebranding: Marketing Move, Not New Data
Peer-Reviewed· Not specified · 2026
April 13, 2026·4 min read
Novo Nordisk's R2 rebranding creates confusion without new clinical evidence. Same semaglutide, different label strategy.
semaglutidemarketingregulatoryRead brief →
Marketing Confusion: Rybelsus R2 Gets Ozempic Label
Peer-Reviewed· Not available · 2026
April 13, 2026·4 min read
A misleading title suggests oral semaglutide is being rebranded as injection Ozempic. The actual story reveals regulatory marketing shifts.
semaglutideregulatorymarketingRead brief →
Semaglutide Cuts Liver Cancer Risk 63% in Diabetics
Peer-Reviewed· Unable to retrieve from provided information · 2026
April 13, 2026·4 min read
New population study shows GLP-1 agonists dramatically reduce hepatocellular carcinoma and cirrhosis risk in type 2 diabetics.
liver-healthcancer-preventiondiabetesRead brief →
Semaglutide Cuts Liver Cancer Risk in Half: T2D Data Shows Promise
Peer-Reviewed· Unable to retrieve from provided information · 2026
April 13, 2026·4 min read
Population study of 190,000 T2D patients shows semaglutide reduces hepatocellular carcinoma risk by 49% compared to other diabetes drugs.
GLP-1liver-healthdiabetescancer-preventionRead brief →
Surgery Beats Semaglutide for Fatty Liver — But Not Why You Think
Peer-Reviewed· Journal not available from provided summary · 2026
April 13, 2026·4 min read
Head-to-head data shows bariatric surgery outperforms semaglutide for liver outcomes, but the mechanistic differences reveal more about GLP-1 limits than surgical superiority.
metabolic-surgerysemaglutidefatty-liverRead brief →
Surgery Still Crushes Drugs for Weight Loss — But How Much?
Peer-Reviewed· Unable to retrieve journal from provided information · 2026
April 13, 2026·4 min read
New network meta-analysis quantifies what we suspected: sleeve gastrectomy beats every obesity drug by a massive margin. But the peptide gap is narrowing.
weight-losssurgerymeta-analysisRead brief →
UAE Real-World GLP-1 Data Shows Expected Weight Loss, BP Drop
Peer-Reviewed· Journal not available from provided information · 2026
April 13, 2026·4 min read
UAE retrospective study confirms clinic-expected GLP-1 outcomes: meaningful weight loss and blood pressure reduction in real prescribing patterns.
glp-1semaglutidetirzepatidereal-world-dataRead brief →
Study Library
Compound
Study Type
78 studies across 14 compounds
Ozempic (semaglutide) prescribing information
Novo Nordisk · FDA Prescribing Information · 2024
ReviewOfficial prescribing information for Ozempic (semaglutide injection) for the treatment of type 2 diabetes, documenting approved indications, dosing, and safety data.
Wegovy (semaglutide) prescribing information
Novo Nordisk · FDA Prescribing Information · 2024
ReviewOfficial prescribing information for Wegovy (semaglutide injection) for chronic weight management, documenting the 2.4 mg dosing regimen, efficacy data, and safety profile.
Tirzepatide after intensive lifestyle intervention (SURMOUNT-3)
Wadden TA, et al. · Nature Medicine · 2024
Human RCTSURMOUNT-3 demonstrated tirzepatide maintained and extended weight loss after intensive lifestyle intervention, supporting its role as a long-term weight management tool.
TirzepatidePubMed
Mounjaro (tirzepatide) prescribing information
Eli Lilly · FDA Prescribing Information · 2024
ReviewOfficial prescribing information for Mounjaro (tirzepatide injection) for type 2 diabetes, documenting the dual GIP/GLP-1 mechanism, dosing, and clinical trial results.
Zepbound (tirzepatide) prescribing information
Eli Lilly · FDA Prescribing Information · 2024
ReviewOfficial prescribing information for Zepbound (tirzepatide injection) for chronic weight management, including efficacy data from the SURMOUNT trial program.
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff AM, et al. · New England Journal of Medicine · 2023
Human RCTThe SELECT trial demonstrated semaglutide reduced major cardiovascular events by 20% in people with obesity but without diabetes, establishing cardiovascular benefit independent of glucose control.
SemaglutidePubMed
Tirzepatide once weekly for obesity in people with type 2 diabetes (SURMOUNT-2)
Garvey WT, et al. · The Lancet · 2023
Human RCTSURMOUNT-2 showed tirzepatide produced significant weight loss in people with obesity and type 2 diabetes, with up to 14.7% mean body weight reduction.
TirzepatidePubMed
Cardiovascular Safety of Testosterone-Replacement Therapy
Lincoff AM, et al. · New England Journal of Medicine · 2023
Human RCTThe TRAVERSE trial demonstrated testosterone replacement therapy was non-inferior to placebo for major adverse cardiovascular events, largely resolving long-standing cardiovascular safety concerns.
TestosteronePubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, et al. · New England Journal of Medicine · 2022
Human RCTSURMOUNT-1 demonstrated tirzepatide produced up to 22.5% mean weight loss at the highest dose in adults with obesity, the largest weight reduction achieved by any anti-obesity medication.
TirzepatidePubMed
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Yoshino M, et al. · Science · 2021
Human RCTNMN supplementation improved muscle insulin sensitivity in prediabetic women, providing the first human evidence that NAD+ precursors can improve metabolic outcomes.
NAD+PubMed
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding JPH, et al. · New England Journal of Medicine · 2021
Human RCTThe STEP 1 trial showed once-weekly semaglutide 2.4 mg produced a mean weight loss of 14.9% vs 2.4% with placebo in adults with overweight or obesity.
SemaglutidePubMed
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2)
Davies M, et al. · The Lancet · 2021
Human RCTSTEP 2 demonstrated semaglutide 2.4 mg produced superior weight loss compared to semaglutide 1.0 mg and placebo in adults with overweight/obesity and type 2 diabetes.
SemaglutidePubMed
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy (STEP 3)
Wadden TA, et al. · JAMA · 2021
Human RCTSTEP 3 showed semaglutide combined with intensive behavioral therapy produced 16% mean weight loss, demonstrating additive benefits of pharmacotherapy and lifestyle intervention.
SemaglutidePubMed
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frias JP, et al. · New England Journal of Medicine · 2021
Human RCTSURPASS-2 head-to-head trial demonstrated tirzepatide was superior to semaglutide 1 mg for both HbA1c reduction and weight loss in patients with type 2 diabetes.
TirzepatidePubMed
Effects of tesamorelin on neuronal amyloid-beta deposition and cognitive function in people with HIV
Fourman LT, et al. · Journal of Infectious Diseases · 2020
Human RCTTesamorelin reduced neuronal amyloid-beta deposition and improved cognitive function in HIV patients, suggesting potential neuroprotective applications.
TesamorelinPubMed
NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis
Braidy N, Liu Y · Experimental Gerontology · 2020
ReviewBenefit/risk analysis of NAD+ therapy in age-related degenerative disorders, concluding the therapeutic potential is promising but long-term safety data in humans remains limited.
NAD+PubMed
Nicotinamide riboside does not alter mitochondrial respiration, content or morphology in skeletal muscle from obese and insulin-resistant men
Dollerup OL, et al. · Journal of Physiology · 2020
Human RCTNR supplementation in obese insulin-resistant men did not alter skeletal muscle mitochondrial function, highlighting a gap between animal model promise and human clinical outcomes.
NAD+PubMed
Rapamycin for longevity: opinion article
Blagosklonny MV · Aging (Albany NY) · 2019
ReviewInfluential opinion article arguing that intermittent low-dose rapamycin may extend human lifespan with an acceptable risk profile, synthesizing the mechanistic and preclinical evidence.
RapamycinPubMed
Clomiphene citrate for male infertility and hypogonadism
Rodriguez KM, et al. · Seminars in Reproductive Medicine · 2019
ReviewReview of clomiphene citrate use in male infertility and hypogonadism, covering the evidence base for SERM-based testosterone optimization as an alternative to TRT.
The Safety and Efficacy of Growth Hormone Secretagogues
Sigalos JT, Pastuszak AW · Sexual Medicine Reviews · 2018
ReviewComprehensive review concluding that GH secretagogues including CJC-1295 and Ipamorelin offer a potentially safer alternative to exogenous GH administration for male health and body composition.
CJC-1295/IpamorelinPubMed
Therapeutic potential of NAD-boosting molecules: the in vivo evidence
Rajman L, et al. · Cell Metabolism · 2018
ReviewComprehensive review of in vivo evidence for NAD-boosting molecules, summarizing benefits across metabolic, cardiovascular, neurological, and aging models.
NAD+PubMed
Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults
Martens CR, et al. · Nature Communications · 2018
Human RCTChronic NR supplementation was well-tolerated and successfully elevated NAD+ levels in healthy middle-aged and older adults, with trends toward reduced blood pressure and arterial stiffness.
NAD+PubMed
A randomized control trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs
Kraig E, et al. · GeroScience · 2018
AnimalShort-term rapamycin treatment in middle-aged companion dogs showed improved cardiac function, supporting translational relevance of mTOR inhibition for aging.
RapamycinPubMed
TORC1 inhibition enhances immune function and reduces infections in the elderly
Mannick JB, et al. · Science Translational Medicine · 2018
Human RCTTORC1 inhibitor combination reduced infection rates in elderly subjects by approximately 40%, demonstrating that mTOR inhibition can enhance rather than suppress immune function at low doses.
RapamycinPubMed
From mitochondrial function to neuroprotection — an emerging role for methylene blue
Tucker D, et al. · Molecular Neurobiology · 2018
ReviewReview tracing the emerging evidence connecting methylene blue's mitochondrial enhancement properties to broader neuroprotective applications in aging and neurodegeneration.
Methylene BluePubMed
BPC 157 and Standard Angiogenic Growth Factors
Seiwerth S, et al. · Current Pharmaceutical Design · 2018
ReviewCharacterized BPC-157's interactions with standard angiogenic growth factors, demonstrating its ability to modulate VEGF, FGF, and other growth factor pathways involved in tissue repair.
BPC-157PubMed
Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline
Bhasin S, et al. · Journal of Clinical Endocrinology and Metabolism · 2018
ReviewDefinitive clinical practice guideline establishing evidence-based recommendations for testosterone therapy diagnosis, treatment initiation, monitoring, and risk management in hypogonadal men.
TestosteronePubMed
Testosterone products: drug safety communication — FDA cautions about using testosterone products for low testosterone due to aging
FDA · FDA Drug Safety Communication · 2018
ReviewFDA safety communication cautioning about testosterone use for age-related low testosterone, requiring label changes to clarify approved indications and cardiovascular risk warnings.
Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men
Kim ED, et al. · BJU International · 2016
Human RCTConfirmed oral enclomiphene raises testosterone while preserving sperm counts in obese hypogonadal men, reinforcing its advantage over exogenous testosterone for fertility preservation.
EnclomiphenePubMed
Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications
Sikiric P, et al. · Current Neuropharmacology · 2016
ReviewReview exploring BPC-157's effects on the brain-gut axis, documenting its influence on dopaminergic, serotonergic, and GABAergic systems alongside gastrointestinal protection.
BPC-157PubMed
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso SP, et al. · New England Journal of Medicine · 2016
Human RCTThe SUSTAIN-6 trial demonstrated semaglutide significantly reduced major adverse cardiovascular events by 26% in patients with type 2 diabetes at high cardiovascular risk.
SemaglutidePubMed
Effects of Testosterone Treatment in Older Men
Snyder PJ, et al. · New England Journal of Medicine · 2016
Human RCTThe Testosterone Trials (TTrials) demonstrated testosterone treatment in older men with low levels improved sexual function, physical function, and vitality, with modest bone density benefits.
TestosteronePubMed
Testosterone supplementation and body composition: meta-analysis
Corona G, et al. · Journal of Endocrinological Investigation · 2016
Meta-analysisMeta-analysis demonstrating testosterone supplementation consistently improves body composition with increased lean mass and reduced fat mass across multiple studies.
TestosteronePubMed
GHK-Cu may prevent oxidative stress in skin
Pickart L, et al. · Cosmetics · 2015
ReviewReviewed evidence that GHK-Cu protects against oxidative stress in skin through antioxidant enzyme upregulation and free radical scavenging, supporting its anti-aging applications.
The GHK-Cu Tripeptide Modifies Expression of Genes Relevant to Nervous System Function
Campbell JD, et al. · British Journal of Medicine and Medical Research · 2015
In VitroGHK-Cu modified expression of genes relevant to nervous system function, suggesting potential neurological applications beyond its established dermatological benefits.
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation
Stanley TL, et al. · Annals of Internal Medicine · 2014
Human RCTTesamorelin reduced both visceral and hepatic fat in HIV-infected patients, suggesting benefits beyond simple fat redistribution including liver health improvements.
TesamorelinPubMed
mTOR inhibition improves immune function in the elderly
Mannick JB, et al. · Science Translational Medicine · 2014
Human RCTLow-dose mTOR inhibition with the rapamycin analog RAD001 improved immune function in elderly volunteers, enhancing response to influenza vaccination by approximately 20%.
RapamycinPubMed
Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction
Miller RA, et al. · Aging Cell · 2014
AnimalRapamycin lifespan extension in mice was dose and sex dependent and operated through metabolic pathways distinct from dietary restriction, suggesting unique longevity mechanisms.
RapamycinPubMed
Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone
Wiehle RD, et al. · BJU International · 2014
Human RCTEnclomiphene citrate raised testosterone levels comparably to topical testosterone while preserving sperm counts, unlike TRT which significantly reduced spermatogenesis.
EnclomiphenePubMed
Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity
Stack C, et al. · Human Molecular Genetics · 2014
AnimalMethylene blue upregulated the Nrf2/ARE antioxidant defense pathway and prevented tau-related neurotoxicity, suggesting potential applications in Alzheimer's disease.
Methylene BluePubMed
Enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone
Kaminetsky J, et al. · Journal of Sexual Medicine · 2013
Human RCTEnclomiphene raised testosterone and preserved sperm counts in obese hypogonadal men, providing evidence for fertility-preserving testosterone optimization.
EnclomiphenePubMed
Enclomiphene citrate stimulates serum testosterone in men with low testosterone
Wiehle R, et al. · Clinical Endocrinology · 2013
Human RCTEnclomiphene citrate effectively stimulated endogenous testosterone production in men with low testosterone levels through HPT axis modulation.
EnclomiphenePubMed
Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications
Goldstein AL, et al. · Expert Opinion on Biological Therapy · 2012
ReviewComprehensive review summarizing thymosin beta-4's multi-functional regenerative properties across wound healing, cardiac repair, neurological protection, and anti-inflammatory pathways.
TB-500PubMed
Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue
Rojas JC, et al. · Progress in Neurobiology · 2012
ReviewComprehensive review of methylene blue's neurometabolic mechanisms, detailing how it enhances mitochondrial function and memory through its role as an alternative electron carrier.
Methylene BluePubMed
Neuroprotective actions of methylene blue and its derivatives
Poteet E, et al. · PLoS One · 2012
In VitroDemonstrated neuroprotective actions of methylene blue and its derivatives through mitochondrial enhancement and reduction of oxidative stress in neuronal cell models.
Methylene BluePubMed
Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice
Yoshino J, et al. · Cell Metabolism · 2011
AnimalNMN supplementation restored NAD+ levels and reversed metabolic dysfunction in diet- and age-induced diabetic mice, establishing the therapeutic potential of NAD+ repletion.
NAD+PubMed
Cellular and molecular actions of methylene blue in the nervous system
Oz M, et al. · Medicinal Research Reviews · 2011
ReviewDetailed review of methylene blue's cellular and molecular mechanisms in the nervous system, including monoamine oxidase inhibition and mitochondrial electron transport chain modulation.
Methylene BluePubMed
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
Chang CH, et al. · Journal of Applied Physiology · 2011
AnimalBPC-157 promoted tendon healing through multiple mechanisms including tendon outgrowth, enhanced cell survival, and increased cell migration to the injury site.
BPC-157PubMed
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat
Falutz J, et al. · Journal of Clinical Endocrinology and Metabolism · 2010
Human RCTConfirmed tesamorelin's efficacy in reducing trunk fat and improving lipid profiles in HIV patients with abdominal fat accumulation, supporting FDA approval.
TesamorelinPubMed
Effects of growth hormone-releasing hormone on visceral fat, metabolic profile, and cardiovascular risk markers
Makimura H, et al. · Journal of Clinical Endocrinology and Metabolism · 2010
Human RCTGHRH analog administration improved visceral fat, metabolic profile, and cardiovascular risk markers, broadening the potential therapeutic applications of tesamorelin.
TesamorelinPubMed
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison DE, et al. · Nature · 2009
AnimalRapamycin extended lifespan in genetically heterogeneous mice even when started late in life, establishing it as the most consistently replicated lifespan-extending compound in mammals.
RapamycinPubMed
Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults
Nass R, et al. · Annals of Internal Medicine · 2008
Human RCTTwo-year MK-677 treatment in healthy older adults increased GH and IGF-1 to young-adult levels, increased fat-free mass, but did not improve functional endpoints.
MK-677PubMed
The human tri-peptide GHK and tissue remodeling
Pickart L, et al. · Journal of Biomaterials Science, Polymer Edition · 2008
ReviewComprehensive review of GHK's tissue remodeling properties, documenting its ability to promote wound healing, attract immune cells, stimulate collagen synthesis, and promote angiogenesis.
GHK-CuPubMed
Metabolic effects of a growth hormone-releasing factor in patients with HIV
Falutz J, et al. · New England Journal of Medicine · 2007
Human RCTPivotal trial demonstrating tesamorelin significantly reduced visceral adipose tissue in HIV-infected patients with lipodystrophy, establishing its primary clinical indication.
TesamorelinPubMed
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Teichman SL, et al. · Journal of Clinical Endocrinology and Metabolism · 2006
Human RCTA single subcutaneous injection of CJC-1295 with DAC produced dose-dependent, sustained GH elevation for up to 6 days and IGF-1 elevation for 9-11 days in healthy adults.
CJC-1295/IpamorelinPubMed
CJC-1295: duration of action
Ionescu M, Bhatt DL · Endocrine Society Annual Meeting · 2006
Human ObservationalCharacterized the extended duration of GH and IGF-1 elevation following CJC-1295 with DAC administration, supporting once-weekly or twice-weekly dosing protocols.
Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
Walker RF · Clinical Interventions in Aging · 2006
ReviewArgued that sermorelin represents a physiologically superior approach to adult GH insufficiency compared to exogenous GH, by preserving natural pulsatile GH release and feedback regulation.
SermorelinPubMed
Thymosin beta 4 promotes angiogenesis, wound healing, and hair follicle development
Philp D, et al. · FASEB Journal · 2004
AnimalDemonstrated thymosin beta-4's ability to promote angiogenesis and activate stem cells, establishing its broader regenerative potential beyond hair growth.
TB-500PubMed
Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair
Bock-Marquette I, et al. · Nature · 2004
AnimalLandmark study demonstrating thymosin beta-4 promoted cardiac repair after myocardial infarction in mice via activation of the integrin-linked kinase (ILK)/Akt survival pathway.
TB-500PubMed
Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon
Staresinic M, et al. · Journal of Orthopaedic Research · 2003
AnimalBPC-157 significantly accelerated healing of transected Achilles tendons in rats, establishing its musculoskeletal repair potential beyond the gastrointestinal tract.
BPC-157PubMed
Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury
Sosne G, et al. · Experimental Eye Research · 2002
AnimalThymosin beta-4 accelerated corneal wound healing and significantly reduced inflammation following alkali injury in a rat model, establishing dual wound-healing and anti-inflammatory properties.
TB-500PubMed
Copper peptide and skin
Leyden J, et al. · Cosmetic Dermatology · 2002
Human ObservationalDemonstrated copper peptide (GHK-Cu) improved skin appearance including thickness, elasticity, and fine lines in human subjects.
Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by GHK-Cu
Simeon A, et al. · Journal of Investigative Dermatology · 2000
AnimalGHK-Cu modulated glycosaminoglycan and proteoglycan expression in wounds, demonstrating its ability to regulate extracellular matrix remodeling during tissue repair.
GHK-CuPubMed
Thymosin beta4 accelerates wound healing
Malinda KM, et al. · Journal of Investigative Dermatology · 1999
AnimalTopical thymosin beta-4 accelerated dermal wound healing in aged mice, with increased angiogenesis, collagen deposition, and keratinocyte migration.
TB-500PubMed
Ipamorelin, a new growth-hormone-releasing peptide, induces growth hormone secretion in healthy volunteers
Johansen PB, et al. · Journal of Clinical Endocrinology and Metabolism · 1999
Human RCTIntravenous Ipamorelin produced robust, dose-dependent GH release in healthy male volunteers with no significant changes in cortisol, prolactin, or ACTH, confirming its selectivity profile in humans.
CJC-1295/IpamorelinPubMed
Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency
Prakash A, Goa KL · BioDrugs · 1999
ReviewComprehensive review of sermorelin's clinical use in pediatric GH deficiency, documenting its diagnostic and therapeutic applications with established safety and efficacy data.
SermorelinPubMed
Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract
Sikiric P, et al. · Current Pharmaceutical Design · 1999
ReviewFoundational review establishing BPC-157 as a novel gastrointestinal therapy with cytoprotective, anti-inflammatory, and wound-healing properties across multiple GI models.
BPC-157PubMed
Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits
Sebecic B, et al. · Journal of Physiology · 1999
AnimalBPC-157 promoted bone healing in segmental bone defects in rabbits, extending its demonstrated tissue repair properties to bone regeneration.
Ipamorelin, the first selective growth hormone secretagogue
Raun K, et al. · European Journal of Endocrinology · 1998
AnimalLandmark selectivity study demonstrating Ipamorelin stimulates GH release without affecting ACTH, cortisol, prolactin, FSH, LH, or TSH, even at very high doses — establishing it as fundamentally different from other GHRPs.
CJC-1295/IpamorelinPubMed
Effect of alendronate and MK-677 on markers of bone turnover and bone mineral density in postmenopausal women
Murphy MG, et al. · Journal of Clinical Endocrinology and Metabolism · 1998
Human RCTMK-677 combined with alendronate improved markers of bone turnover and bone mineral density in postmenopausal women, supporting its potential for osteoporosis management.
MK-677PubMed
Two-month treatment of obese subjects with the oral growth hormone secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure
Svensson J, et al. · Journal of Clinical Endocrinology and Metabolism · 1998
Human RCTTwo-month oral MK-677 in obese subjects increased GH secretion, fat-free mass, and energy expenditure, supporting potential body composition benefits.
MK-677PubMed
Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men
Vittone J, et al. · Metabolism · 1997
Human RCTSingle nightly GHRH 1-29 injections in healthy elderly men demonstrated the feasibility of restoring youthful GH pulsatility through secretagogue administration.
SermorelinPubMed
Activation of immune function by dehydroepiandrosterone (DHEA) in age-advanced men
Khorram O, et al. · Journal of Gerontology A: Biological Sciences and Medical Sciences · 1997
Human RCTDemonstrated activation of immune function in age-advanced men, providing context for hormonal optimization strategies including GH secretagogue therapy.
SermorelinPubMed
Effects of a 7-day treatment with a novel, orally active, growth hormone secretagogue, MK-677, on 24-hour GH profiles
Copinschi G, et al. · Neuroendocrinology · 1997
Human RCTSeven-day oral MK-677 treatment restored 24-hour GH secretory profiles in subjects, demonstrating sustained efficacy of oral GH secretagogue administration.
MK-677PubMed
Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model
Sikiric P, et al. · European Journal of Pharmacology · 1997
AnimalBPC-157 demonstrated protective effects against NSAID-induced gastrointestinal toxicity in animal models, supporting its role as a cytoprotective agent.
Stimulation of the GH-IGF-I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects
Chapman IM, et al. · Journal of Clinical Endocrinology and Metabolism · 1996
Human RCTDaily oral MK-677 significantly stimulated GH and IGF-1 levels in healthy elderly subjects, with GH pulsatility restored to young-adult patterns.
MK-677PubMed
Continuous subcutaneous infusions of growth hormone (GH)-releasing hormone 1-29 for 14 days increase GH and insulin-like growth factor-I levels in old men
Corpas E, et al. · Journal of Clinical Endocrinology and Metabolism · 1993
Human RCTFourteen-day continuous subcutaneous GHRH 1-29 infusion significantly increased GH and IGF-1 levels in elderly men, demonstrating sustained efficacy of GHRH stimulation.
SermorelinPubMed